| P2093 | author name string | Alan I Green | |
| | Mary F Brunette | |
| | Robert M Roth | |
| P2860 | cites work | Addictive Drugs and Brain Stimulation Reward | Q22241983 |
| | A review of MRI findings in schizophrenia | Q24657354 |
| | Brain reward circuitry: insights from unsensed incentives | Q28207855 |
| | Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors | Q28209521 |
| | The self-medication hypothesis of substance use disorders: a reconsideration and recent applications | Q28255574 |
| | Moderate drinking among people with severe mental illness | Q28262625 |
| | Neural correlates of behavioral preference for culturally familiar drinks | Q28286977 |
| | A neurobiological basis for substance abuse comorbidity in schizophrenia | Q28347063 |
| | A Review of Treatments for People with Severe Mental Illnesses and Co-Occurring Substance Use Disorders. | Q29010591 |
| | Neural mechanisms of anhedonia in schizophrenia: a PET study of response to unpleasant and pleasant odors. | Q30656905 |
| | The addicted human brain: insights from imaging studies | Q30794301 |
| | The neural circuitry of reward and its relevance to psychiatric disorders | Q30957200 |
| | Functional magnetic resonance imaging of cocaine craving | Q31796598 |
| | Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment | Q33186724 |
| | Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes | Q33586386 |
| | Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? | Q33659891 |
| | Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey | Q33827207 |
| | Substance use disorders in schizophrenia: review, integration, and a proposed model | Q33865680 |
| | Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia | Q34056092 |
| | Alcohol dependence and hospitalization in schizophrenia | Q78064877 |
| | Preliminary evidence of improved verbal working memory performance and normalization of task-related frontal lobe activation in schizophrenia following cognitive exercises. | Q52024215 |
| | Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. | Q55056971 |
| | Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity | Q59668672 |
| | Is Substance Abuse in Schizophrenia Related to Impulsivity, Sensation Seeking, or Anhedonia? | Q59668692 |
| | Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence | Q71226356 |
| | Haloperidol increases smoking in patients with schizophrenia | Q72061658 |
| | Relationship between the five-factor model of personality and Axis I disorders in a nonclinical sample | Q72082286 |
| | Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients | Q72936316 |
| | Relationships between symptoms of schizophrenia and substance abuse | Q73089365 |
| | Heroin and schizophrenia: subjective responses to abused drugs in dually diagnosed patients | Q73491983 |
| | Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups | Q73649260 |
| | The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia | Q73967057 |
| | A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder | Q74499308 |
| | Beauty in a smile: the role of medial orbitofrontal cortex in facial attractiveness. | Q34161830 |
| | Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden | Q34201663 |
| | A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence | Q34417561 |
| | Precipitation and determination of the onset and course of schizophrenia by substance abuse--a retrospective and prospective study of 232 population-based first illness episodes | Q34522385 |
| | A pilot trial of topiramate for the treatment of cocaine dependence | Q34649737 |
| | Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature | Q34989186 |
| | Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. | Q35057924 |
| | Clinical implications of reinforcement as a determinant of substance use disorders | Q35639040 |
| | Schizophrenia: diathesis-stress revisited | Q35898047 |
| | Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability | Q35950888 |
| | Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia | Q36500321 |
| | Pharmacological treatment of substance-abusing schizophrenic patients | Q37586675 |
| | A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI. | Q38429790 |
| | Marijuana use in schizophrenia: a clear hazard | Q39211238 |
| | Alcohol use and abuse in schizophrenia. A prospective community study | Q39281419 |
| | Acute alcohol effects on neuronal and attentional processing: striatal reward system and inhibitory sensory interactions under acute ethanol challenge | Q39681875 |
| | An analysis of cue reactivity among persons with and without schizophrenia who are addicted to cocaine | Q40618182 |
| | Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence | Q40629875 |
| | Effects of antipsychotic drugs on operant responding after acute and repeated administration | Q40656209 |
| | alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs | Q40670096 |
| | A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy | Q40762464 |
| | Assessing substance use disorder in persons with severe mental illness | Q41074201 |
| | Subjective experiences related to alcohol use among schizophrenics | Q41158129 |
| | Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature | Q41261022 |
| | Schizophrenia: a neural diathesis-stress model | Q41616625 |
| | Substance abuse in schizophrenia: a review | Q41738239 |
| | Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study | Q42539637 |
| | Gabapentin reduces cocaine use among addicts from a community clinic sample | Q42618199 |
| | Quetiapine in bipolar disorder and cocaine dependence | Q42692308 |
| | Six-month outcomes for patients who switched to olanzapine treatment | Q43556853 |
| | Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia | Q43559127 |
| | Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia | Q43562512 |
| | A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics | Q43734438 |
| | Divalproex loading in the treatment of cocaine dependence | Q43805757 |
| | Olanzapine treatment for patients with schizophrenia and substance abuse | Q43845727 |
| | Concomitant clozapine reduces smoking in patients treated with risperidone | Q43852515 |
| | Motivational interviewing among psychiatric in-patients with substance use disorders | Q44115969 |
| | Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia | Q44137459 |
| | Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder | Q44137472 |
| | The association between high nicotine dependence and severe mental illness may be consistent across countries. | Q44167479 |
| | Development of alcohol-associated cues and cue-induced brain activation in alcoholics | Q44180647 |
| | Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism | Q44239950 |
| | Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone | Q44264708 |
| | Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome | Q44345946 |
| | Testing hypotheses about the relationship between cannabis use and psychosis | Q44487800 |
| | Alcohol promotes dopamine release in the human nucleus accumbens | Q44492239 |
| | A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders | Q44498548 |
| | Disulfiram treatment for alcoholism in severe mental illness | Q44506673 |
| | Persistent cue-evoked activity of accumbens neurons after prolonged abstinence from self-administered cocaine. | Q44548755 |
| | Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. | Q44550790 |
| | Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia | Q44666887 |
| | Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. | Q44681644 |
| | Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium | Q44758235 |
| | Investigating the use of contingency management in the treatment of cocaine abuse among individuals with schizophrenia: a feasibility study | Q44766856 |
| | First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol | Q44827853 |
| | Outcomes of managing disability benefits among patients with substance dependence and severe mental illness | Q44832319 |
| | Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity | Q44867680 |
| | Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia | Q44935786 |
| | Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey | Q44986547 |
| | Evolving use of buprenorphine in the treatment of addiction | Q44996722 |
| | A brief motivational intervention for substance misuse in recent-onset psychosis | Q45060877 |
| | Neuroscience. Addiction as compulsive reward prediction. | Q45182823 |
| | Addiction as a computational process gone awry | Q45182826 |
| | Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study | Q45209951 |
| | Choosing between small, likely rewards and large, unlikely rewards activates inferior and orbital prefrontal cortex | Q48093813 |
| | Drug-activation of brain reward pathways | Q48405857 |
| | Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder | Q48431922 |
| | Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence | Q48692470 |
| | Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: a feasibility study | Q48693636 |
| | Patterns of current and lifetime substance use in schizophrenia | Q48715154 |
| | Event-related brain potentials to high-incentive stimuli in unmedicated schizophrenic patients. | Q48798057 |
| | Acute marijuana effects on rCBF and cognition: a PET study | Q49153494 |
| | Examining an affect regulation model of substance abuse in schizophrenia. The role of traits and coping. | Q51091578 |
| | Anhedonia, positive and negative affect, and social functioning in schizophrenia. | Q51094944 |
| | Impact of an early psychosis program on substance use. | Q51963985 |
| | Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. | Q51969974 |
| | Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. | Q51980676 |
| | The cost of treating substance abuse patients with and without comorbid psychiatric disorders. | Q51981172 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 283-291 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Current Psychiatry Reports | Q25245507 |
| P1476 | title | Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? | |
| P478 | volume | 7 | |